Progesterone for treatment of symptomatic menopausal women

References

• Speroff L. It’s time to stop using the word ‘replacement’. Maturitas 2000;34:1–3
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in health postmenopausal women: prinicipal results from the women’s health initiative randomized control trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Simon JA. What’s new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric 2012;15(Suppl 1):3–10
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249–60
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015;100:3975–4011
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an endocrine society scientific statement. JCEM 2010;95(Suppl 1):S1–S66
   Web of Science ®Google Scholar
• Krieger N, Lowy I, Aronowitz R, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health 2005;59:740–8
   PubMed Web of Science ®Google Scholar
• Baxter S, Prior JC, The estrogen errors: why progesterone is better for women's health. Westport: Praeger Publishers; 2009
   Google Scholar
• Frank RT, The female sex hormone. Springfield (IL): Charles C. Thomas; 1929
   Google Scholar
• Rosano GM, Sarais C, Zoncu S, Mercuro G. The relative effects of progesterone and progestins in hormone replacement therapy. Hum Reprod 2000;15(Suppl 1):60–73
   PubMed Web of Science ®Google Scholar
• Oudshoorn N, Beyond the natural body: an archeology of sex hormones. London: Routledge; 1994
   Google Scholar
• Lignieres B, Vincens M. Differential effects of exogenous oestradiol and progesterone on mood in post-menopausal women: individual dose/effect relationship. Maturitas 1982;4:67–72
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013;34:171–208
   PubMed Web of Science ®Google Scholar
• Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001;13:453–64
   PubMed Web of Science ®Google Scholar
• Kronenberg F, Cote LJ, Linkie DM, Dyrenfurth I, Downey JA. Menopausal hot flashes: thermoregulatory, cardiovascular and circulating catecholamine and LH changes. Maturitas 1984;6:31–43
   PubMed Web of Science ®Google Scholar
• Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric 2008;11:32–43
   PubMed Web of Science ®Google Scholar
• Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463–73
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10:197–214
   PubMed Web of Science ®Google Scholar
• Thunell L, Stadberg E, Milsom I, Mattsson LAA. longitudinal population study of climacteric symptoms and their treatment in a random sample of Swedish women. Climacteric 2004;7:357–65
   PubMed Web of Science ®Google Scholar
• Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol 2003;102:1233–9
   PubMed Web of Science ®Google Scholar
• Gangar KF, Cust MP, Whitehead MI. Symptoms of oestrogen deficiency associated with supraphysiological plasma estradiol concentrations in women with oestradiol implants. Br Med J 1993;299:601–2
   Google Scholar
• Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117:1095–104
   PubMed Web of Science ®Google Scholar
• Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998;19:397–428
   PubMed Web of Science ®Google Scholar
• Hale GE, Hitchcock CL, Williams LA, Vigna YM, Prior JC. Cyclicity of breast tenderness and night-time vasomotor symptoms in mid-life women: information collected using the Daily Perimenopause Diary. Climacteric 2003;6:128–39
   PubMed Web of Science ®Google Scholar
• Hale GE, Hughes CL, Burger HG, Robertson DM, Fraser IS. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause 2009;16:50–9
   PubMed Web of Science ®Google Scholar
• Schwingl PJ, Hulka BS, Harlow SD. Risk factors for menopausal hot flashes. Obstet Gynecol 1994;84:29–34
   PubMed Web of Science ®Google Scholar
• Thurston RC, Sowers MR, Chang Y, et al. Adiposity and reporting of vasomotor symptoms among midlife women: the study of women’s health across the nation. Am J Epidemiol 2008;167:78–85
   PubMed Web of Science ®Google Scholar
• Greendale GA, Wight RG, Huang MH, et al. Menopause-associated symptoms and cognitive performance: results from the study of women's health across the nation. Am J Epidemiol 2010;171:1214–24
   PubMed Web of Science ®Google Scholar
• Swartzman LC, Edelberg R, Kemmann E. Impact of stress on objectively recorded menopausal hot flushes and on flush report bias. Health Psychol 1990;9:529–45
   PubMed Web of Science ®Google Scholar
• Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. J Steroid Biochem Mol Biol 2014;142:115–20
   PubMed Web of Science ®Google Scholar
• Alder E. The Blatt-Kupperman menopausal index: a critique. Maturitas 1998;29:19–24
   PubMed Web of Science ®Google Scholar
• Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25–31
   PubMed Web of Science ®Google Scholar
• Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, LaVasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280–90
   PubMed Web of Science ®Google Scholar
• Prior JC, Alojado N, McKay DW, Vigna YM. No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: double-blind, placebo-controlled, cross-over trial. Obstet Gynecol 1994;83:24–8
   PubMed Web of Science ®Google Scholar
• Prior JC, Nielsen JD, Hitchcock CL, Williams LA, Vigna YM, Dean CB. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci (Lond) 2007;112:517–25
   PubMed Web of Science ®Google Scholar
• Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. Menopause 2018 Mar 12. doi: 10.1097/GME.0000000000001090. [Epub ahead of print]
   PubMedGoogle Scholar
• Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002;20:1449–55
   PubMed Web of Science ®Google Scholar
• Franco OH, Chowdhury R, Troup J, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016;315:2554–63
   PubMed Web of Science ®Google Scholar
• Kroenke CH, Caan BJ, Stefanick ML, et al. Effects of a dietary intervention and weight change on vasomotor symptoms in the women's health initiative. Menopause 2012;19:980–8
   PubMed Web of Science ®Google Scholar
• Dormire SL, Reame NK. Menopausal hot flash frequency changes in response to experimental manipulation of blood glucose. Nurs Res 2003;52:338–43
   PubMed Web of Science ®Google Scholar
• Sarri G, Pedder H, Dias S, Guo Y, Lumsden MA. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the national institute for health and care excellence guideline on menopause. BJOG 2017;124:1514–23
   PubMed Web of Science ®Google Scholar
• Ee C, French SD, Xue CC, Pirotta M, Teede H. Acupuncture for menopausal hot flashes: clinical evidence update and its relevance to decision making. Menopause 2017;24:980–7
   PubMed Web of Science ®Google Scholar
• Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 2013;20:291–8
   PubMed Web of Science ®Google Scholar
• Lipov EG, Lipov S, Joshi JR, Santucci VD, Slavin KV, Beck Vigue SG. Stellate ganglion block may relieve hot flashes by interrupting the sympathetic nervous system. Med Hypotheses 2007;69:758–63
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;CD002978
   PubMedGoogle Scholar
• Prior JC. Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence. Curr Opin Endocrinol Diabetes Obes 2015;22:495–501
   PubMed Web of Science ®Google Scholar
• Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225–8
   PubMed Web of Science ®Google Scholar
• Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003;10:13–18
   PubMed Web of Science ®Google Scholar
• Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161–75
   PubMed Web of Science ®Google Scholar
• Benster B, Carey A, Wadsworth F, Vashisht A, Domoney C, Studd J. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause Int 2009;15:63–9
   PubMedGoogle Scholar
• Stephenson K, Price C, Kurdowska A, et al. Topical progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women. Blood 2004;104:5318
   Web of Science ®Google Scholar
• Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266–301
   PubMed Web of Science ®Google Scholar
• Blank SK, McCartney CR, Marshall JC. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update 2006;12:351–61
   PubMed Web of Science ®Google Scholar
• Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms in healthy postmenopausal women–a placebo-controlled randomized trial. Menopause 2012;19:886–93
   PubMed Web of Science ®Google Scholar
• Simon JA, Robinson DE, Andrews MC, et al. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril 1993;60:26–33
   PubMed Web of Science ®Google Scholar
• Prior JC, Cameron A, Hitchcock CL, et al. Oral micronized progesterone beneficial for perimenopausal hot flushes/flashes and night sweats. Abstract. Endocr Rev 2018;39
   Google Scholar
• Prior JC, Hitchcock CL. Progesterone for hot flush and night sweat treatment–effectiveness for severe vasomotor symptoms and lack of withdrawal rebound. Gynecol Endocrinol 2012;28(Suppl 2):7–11
   PubMed Web of Science ®Google Scholar
• Carroll DG, Kelley KW. Use of antidepressants for management of hot flashes. Pharmacotherapy 2009;29:1357–74
   PubMed Web of Science ®Google Scholar
• Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267–74
   PubMed Web of Science ®Google Scholar
• Mather KJ, Norman EG, Prior JC, Elliott TG. Preserved forearm endothelial responses with acute exposure to progesterone: a randomized cross-over trial of 17-b estradiol, progesterone, and 17-b estradiol with progesterone in healthy menopausal women. J Clin Endocrinol Metab 2000;85:4644–9
   PubMed Web of Science ®Google Scholar
• Prior JC, Elliott TG, Norman E, Stajic V, Hitchcock CL. Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLOS One 2014;9:e84698
   PubMed Web of Science ®Google Scholar
• Prior JC, Naess M, Langhammer A, Forsmo S. Ovulation prevalence in women with spontaneous normal-length menstrual cycles–a population-based cohort from HUNT3, Norway. PLOS One 2015;10:e0134473
   PubMed Web of Science ®Google Scholar
• Prior JC. Progesterone within ovulatory menstrual cycles needed for cardiovascular protection–an evidence-based hypothesis. J Restorat Med 2014;3:85–103
   Google Scholar
• Chang KJ, Lee TTY, Linares-Cruz G, Fournier S, de Lignieres B. Influence of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785–91
   PubMed Web of Science ®Google Scholar
• Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963–9
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLOS One 2013;8:e78016
   PubMed Web of Science ®Google Scholar
• Asi N, Mohammed K, Haydour Q, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev 2016;5:121
   PubMedGoogle Scholar
• Nielsen HK, Brixen K, Bouillon R, Mosekilde L. Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab 1990;70:1431–7
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Scarabin PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas 2011;70:354–60
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Spencer-Gardner C, Gotts G, Brown JB, Smith MA. Progesterone and the premenstrual syndrome: a double blind crossover trial. Br Med J 1985;290:1617–21
   PubMed Web of Science ®Google Scholar
• Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 2012;3:CD003415
   Google Scholar
• Schussler P, Kluge M, Yassouridis A, et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology 2008;33:1124–31
   PubMed Web of Science ®Google Scholar
• Caufriez A, Leproult R, L’hermite-Baleriaux M, Kerkhofs M, Copinschi G. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. J Clin Endocrinol Metab 2011;96:E614–23
   PubMed Web of Science ®Google Scholar
• Prior JC, Hitchcock CL, Vigna YM, Seifert-Klauss V. Premenopausal trabecular bone loss is associated with a family history of fragility fracture. Geburtshilfe Frauenhilfe Sci 2016;76:1–8
   Web of Science ®Google Scholar
• Lentle B, Cheung AM, Hanley DA, et al. Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J 2011;62:243–50
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668–76
   PubMed Web of Science ®Google Scholar
• Prior JC, Vigna YM, Wark JD, et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 1997;12:1851–63
   PubMed Web of Science ®Google Scholar
• Prior JC. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric 2018;21:366–74
   PubMed Web of Science ®Google Scholar
• Prior JC, Seifert-Klauss VR, Giustini D, Adachi JD, Kalyan S, Goshtasebi A. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy–a systematic review and meta-analysis of controlled trials with direct randomization. J Musculoskelet Neuronal Interact 2017;17:146–54
   PubMed Web of Science ®Google Scholar